Technical Data
FNTB, NT (Protein Farnesyltransferase Subunit beta, FTase-beta, CAAX Farnesyltransferase Subunit beta, RAS Proteins Prenyltransferase Subunit beta)
Eukaryotic cells contain 3 different types of prenyltransferases that attach either a farnesyl group (15 carbons) or a geranylgeranyl group (20 carbons) in thioether linkage to C-terminal cysteine residues in a variety of proteins. These posttranslational modifications provide a mechanism for membrane localization of proteins that lack a transmembrane domain. CAAX farnesyltransferase (FTase) attaches a farnesyl group from farnesyl pyrophosphate to cysteine residues at the fourth position from the C terminus of proteins that end in the CAAX box, where C is cysteine, A is usually but not always an aliphatic amino acid, and X is typically methionine or serine. This enzyme has the ability to farnesylate peptides as short as 4 residues in length that conform to the CAAX consensus sequence. The gene for the beta subunit of CAAX farnesyltransferase (FNTB) has been pinpointed to 14q23-q24 by Southern blot hybridization and PCR analyses of panels of human/Chinese hamster somatic cell hybrid lines and by fluorescence chromosomal in situ hybridization.

Suitable for use in ELISA, Western Blot, and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
ELISA: 1:1,000
Western Blot: 1:100-1:500
Immunohistochemistry: 1:50-1:100
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
200ul-20CBlue IceHumanRabbit
As reported
Synthetic peptide selected from the N-terminal region of human FNTB (KLH).
Purified by Protein G affinity chromatography.
Supplied as a liquid in PBS, 0.09% sodium azide.
Recognizes human FNTB.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Lobell, R.B., et al., Cancer Res. 61(24):8758-8768 (2001). 2. Wang, T., et al., Science 271(5252):1120-1122 (1996). 3. Andres, D.A., et al., Genomics 18(1):105-112 (1993). 4. Omer, C.A., et al., Biochemistry 32(19):5167-5176 (1993).